ALKERMES | ALKS - Gross Profit On Sales


ALKERMES reported $375.31M in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
AbbVie USD 14.39B 1.85B Jun/2026
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
ALKERMES USD 375.31M 43.98M Jun/2026
Amgen USD 5.87B 1.02B Mar/2026
Biogen USD 2.12B 307M Jun/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Coherus Biosciences USD 8.7M 853K Dec/2025
Eli Lilly USD 16.22B 301.7M Mar/2026
Gilead Sciences USD 6.8B 1.29B Jun/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Ionis Pharmaceuticals USD 265M 22M Jun/2026
J&J USD 18.55B 1.31B Jun/2026
Merck USD 12.09B 1.24B Mar/2026
Minerva Neurosciences -4.27M 26.79M Dec/2024
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Otsuka Holdings JPY 456.25B 1.16B Mar/2026
Pfizer USD -248M 11.29B Jun/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026